Alectinib in untreated anaplastic lymphoma kinase-positive non-small cell lung cancer

Anne-Marie Ruppert^{1

2}, Xavier Mignard¹, Marie Wislez^{1

2}

Affiliations

¹ Sorbonne Universités, UPMC Univ Paris 06, GRC n°04, Theranoscan, F-75252, Paris, France.
² AP-HP, Hôpital Tenon, Service de Pneumologie, F-75970, Paris, France.

Editorial

Anne-Marie Ruppert et al. Ann Transl Med. 2017 Dec.

. 2017 Dec;5(23):460.

doi: 10.21037/atm.2017.09.05.

Anne-Marie Ruppert^{1

2}, Xavier Mignard¹, Marie Wislez^{1

2}

¹ Sorbonne Universités, UPMC Univ Paris 06, GRC n°04, Theranoscan, F-75252, Paris, France.
² AP-HP, Hôpital Tenon, Service de Pneumologie, F-75970, Paris, France.

No abstract available

Conflict of interest statement

Conflicts of Interest: The authors have no conflicts of interest to declare.

Alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial.
Hida T, Nokihara H, Kondo M, Kim YH, Azuma K, Seto T, Takiguchi Y, Nishio M, Yoshioka H, Imamura F, Hotta K, Watanabe S, Goto K, Satouchi M, Kozuki T, Shukuya T, Nakagawa K, Mitsudomi T, Yamamoto N, Asakawa T, Asabe R, Tanaka T, Tamura T. Hida T, et al. Lancet. 2017 Jul 1;390(10089):29-39. doi: 10.1016/S0140-6736(17)30565-2. Epub 2017 May 10. Lancet. 2017. PMID: 28501140 Clinical Trial.

1. Solomon B, Varella-Garcia M, Camidge DR. ALK gene rearrangements: a new therapeutic target in a molecularly defined subset of non-small cell lung cancer. J Thorac Oncol 2009;4:1450-4. 10.1097/JTO.0b013e3181c4dedb - DOI - PubMed
1. Shaw AT, Kim DW, Nakagawa K, et al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med 2013;368:2385-94. 10.1056/NEJMoa1214886 - DOI - PubMed
1. Ou SH, Ahn JS, De Petris L, et al. Alectinib in crizotinib-refractory ALK-rearranged non-small-cell lung cancer: a phase ii global study. J Clin Oncol 2016;34:661-8. 10.1200/JCO.2015.63.9443 - DOI - PubMed
1. Shaw AT, Kim DW, Mehra R, et al. Ceritinib in ALK-rearranged non-small-cell lung cancer. N Engl J Med 2014;370:1189-97. 10.1056/NEJMoa1311107 - DOI - PMC - PubMed
1. Shaw AT, Kim TM, Crinò L, et al. Ceritinib versus chemotherapy in patients with ALK-rearranged non-small-cell lung cancer previously given chemotherapy and crizotinib (ASCEND-5): a randomised, controlled, open-label, phase 3 trial. Lancet Oncol 2017;18:874-86. 10.1016/S1470-2045(17)30339-X - DOI - PubMed